Back to Search
Start Over
Active Cu(II), Mn(II) and Ag(I) 1,10-phenanthroline/1,10-phenanthroline-5,6-dione/dicarboxylate chelates: effects on Scedosporium .
- Source :
-
Future microbiology [Future Microbiol] 2023 Nov; Vol. 18, pp. 1049-1059. Date of Electronic Publication: 2023 Jun 07. - Publication Year :
- 2023
-
Abstract
- Background: Scedosporium/Lomentospora species are human pathogens that are resistant to almost all antifungals currently available in clinical practice. Methods: The effects of 16 1,10-phenanthroline (phen)/1,10-phenanthroline-5,6-dione/dicarboxylate chelates containing Cu(II), Mn(II) and Ag(I) against Scedosporium apiospermum , Scedosporium minutisporum , Scedosporium aurantiacum and Lomentospora prolificans were evaluated. Results: To different degrees, all of the test chelates inhibited the viability of planktonic conidial cells, displaying MICs ranging from 0.029 to 72.08 μM. Generally, Mn(II)-containing chelates were the least toxic to lung epithelial cells, particularly [Mn <subscript>2</subscript> (oda)(phen) <subscript>4</subscript> (H <subscript>2</subscript> O) <subscript>2</subscript> ][Mn <subscript>2</subscript> (oda)(phen) <subscript>4</subscript> (oda) <subscript>2</subscript> ].4H <subscript>2</subscript> O (MICs: 1.62-3.25 μM: selectivity indexes >64). Moreover, this manganese-based chelate reduced the biofilm biomass formation and diminished the mature biofilm viability. Conclusion: [Mn <subscript>2</subscript> (oda)(phen) <subscript>4</subscript> (H <subscript>2</subscript> O) <subscript>2</subscript> ][Mn <subscript>2</subscript> (oda)(phen) <subscript>4</subscript> (oda) <subscript>2</subscript> ].4H <subscript>2</subscript> O opens a new chemotherapeutic avenue for the deactivation of these emergent, multidrug-resistant filamentous fungi.
Details
- Language :
- English
- ISSN :
- 1746-0921
- Volume :
- 18
- Database :
- MEDLINE
- Journal :
- Future microbiology
- Publication Type :
- Academic Journal
- Accession number :
- 37284767
- Full Text :
- https://doi.org/10.2217/fmb-2022-0202